---
layout: default
title: Benazepril Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 124
evidence_level: L5
indication_count: 0
---

# Benazepril Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Benazepril Hydrochloride: Drug Repurposing Evaluation — Preliminary Report

## One-Sentence Summary

Benazepril Hydrochloride is an ACE inhibitor currently marketed in Malaysia with 2 registered products. **No new indications have been predicted by TxGNN at this time**, and critical data gaps (DrugBank ID, MOA, approved indication text, and safety information) must be resolved before a full evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | *(Data not available — license indication text is empty)* |
| Predicted New Indication | **None** — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No prediction, no studies to evaluate) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 2 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

There is currently **no TxGNN prediction** available for Benazepril Hydrochloride. The `predicted_indications` array is empty, meaning the model either has not been run for this drug or no candidates met the scoring threshold.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on publicly known information, Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. It is widely used for the treatment of hypertension and congestive heart failure. This class of drugs has also been investigated for renoprotective effects in diabetic nephropathy and other conditions.

Before a drug repurposing assessment can proceed, the TxGNN prediction pipeline must be executed with a valid DrugBank mapping for Benazepril (DrugBank ID: **DB00542**, based on known public data) to generate candidate indications.

---

## Clinical Trial Evidence

Currently no predicted indication to search against. Clinical trial evidence will be gathered once a TxGNN prediction is available.

---

## Literature Evidence

Currently no predicted indication to search against. Literature evidence will be gathered once a TxGNN prediction is available.

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| *(empty)* | *(empty)* | *(empty)* | *(empty)* |
| *(empty)* | *(empty)* | *(empty)* | *(empty)* |

> **Note:** Two registrations were found by the NPRA query (query date: 2026-03-27), but the license detail fields (authorization number, product name, dosage form, approved indication) are all empty in this evidence pack. These need to be re-extracted from the NPRA database.

---

## Safety Considerations

> Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) are currently missing from this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evaluation cannot proceed because there are no TxGNN predicted indications and multiple critical data gaps remain unresolved. The evidence pack is incomplete at the most fundamental level — without a predicted indication, no repurposing assessment can be performed.

**To proceed, the following is needed:**

1. **DrugBank ID mapping** — Confirm DrugBank ID (likely DB00542) and integrate into the evidence pack
2. **Re-run TxGNN prediction** — Execute the KG and DL prediction pipeline with the correct DrugBank mapping to generate candidate indications
3. **Populate NPRA license details** — Re-query the NPRA database to fill in authorization numbers, product names, dosage forms, and approved indication text for the 2 registered products
4. **Obtain MOA data** — Query DrugBank API to retrieve the mechanism of action (ACE inhibition pathway)
5. **Obtain safety data** — Download and parse the package insert (仿單) PDF from NPRA/manufacturer to extract warnings, contraindications, and drug interaction information
6. **Evidence collection** — Once a predicted indication is available, run ClinicalTrials.gov, PubMed, and ICTRP collectors for supporting evidence

---

### Data Gaps Summary

| ID | Item | Severity | Remediation |
|----|------|----------|-------------|
| DG001 | Package insert warnings/contraindications | **Blocking** | Download package insert PDF from NPRA and parse |
| DG002 | Mechanism of Action (MOA) | High | Query DrugBank API |
| — | DrugBank ID | High | Map BENAZEPRIL HYDROCHLORIDE → DB00542 |
| — | TxGNN predicted indications | **Blocking** | Re-run prediction pipeline |
| — | NPRA license details | Medium | Re-query NPRA with complete field extraction |
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

